StockData

Inovio Pharmaceuticals vs Kazia Therapeutics

INO and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INO and KZIA compare

Kazia Therapeutics grew revenue faster over the last twelve months (−98.2% versus −100% for Inovio Pharmaceuticals).

Inovio Pharmaceuticals scores higher on the StockData Score (4 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINOKZIA
Size and price
Market cap$169M–
Share price$1.63$5.31
Change, 1 year−20.5%−15.3%
Change, 5 years−98.1%−98.9%
Beta (5Y)−0.264.08
Employees2714
StockData Score
Total score4 (better)1
Valuation score00
Growth score00
Performance score00
Health score4 (better)1
Dividend score00
Valuation
P/B38.6×–
FCF yield−47.9%–
Growth
Revenue growth (TTM)−100%−98.2% (better)
Revenue growth, 5Y average−61.2%–
Profitability
Net margin–−49291%
Return on equity−410%–
Financial health
Debt / equity0.00–
Current ratio1.002.87 (better)
Altman Z-score−55.23–
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield−22.6%–
Shareholder yield−22.6%–
Ownership
Held by institutions31.7%0.45%
Held by insiders0.38%0.29%
Superinvestors holding–1
Short interest, % of float21.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.